Tomoko Freshwater

Phase II Study of WEE1 Inhibitor AZD1775 Plus Carboplatin in Patients With <i>TP53</i>-Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy Within 3 Months

Suzanne Leijen, Robin M.J.M. van Geel, Gabe S. Sonke et al. · Journal of Clinical Oncology · 2016 · 343 citations · Full text

Medicine, Oncology, Pharmacology +16

Phase I Study of Single-Agent AZD1775 (MK-1775), a Wee1 Kinase Inhibitor, in Patients With Refractory Solid Tumors

T. Khanh, Deborah Wilsker, Jiuping Ji et al. · Journal of Clinical Oncology · 2015 · 322 citations · Full text

Medicine, Oncology, Pharmacology +13

Phase I Study Evaluating WEE1 Inhibitor AZD1775 As Monotherapy and in Combination With Gemcitabine, Cisplatin, or Carboplatin in Patients With Advanced Solid Tumors

Suzanne Leijen, Robin M.J.M. van Geel, Anna C. Pavlick et al. · Journal of Clinical Oncology · 2016 · 269 citations · Full text

Medicine, Oncology, Pharmacology +14

Phase I Dose-Escalation Trial of Checkpoint Kinase 1 Inhibitor MK-8776 As Monotherapy and in Combination With Gemcitabine in Patients With Advanced Solid Tumors

Adil Daud, Michelle T. Ashworth, Jonathan Strosberg et al. · Journal of Clinical Oncology · 2015 · 186 citations · Full text

Medicine, Oncology, Pharmacology +17

Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer

Manash Chatterjee, David C. Turner, Enriqueta Felip et al. · Annals of Oncology · 2016 · 162 citations · Full text

Medicine, Oncology, Pharmacology +12